US regulators are already reviewing data from a later-line trial, but Taiho now says it could seek a first-line indication for the EGFR inhibitor.

The biotech will use the funds to advance its pipeline of epigenetic medicines, starting with its candidate EPI-321 for a type of muscular dystrophy.

NEW YORK – Akeso Bio has launched a Phase II study of a bispecific antibody-drug conjugate in combination with its bispecific antibody ivonescimab for advanced breast cancer. The Zhongshan, ...

NEW YORK – Sangamo Therapeutics has auctioned assets for up to $263.6 million, with PTC Therapeutics winning its gene therapy program in Fabry disease and Eli Lilly its platform technologies and prion ...

The firm reported median overall survival of 26 months in patients with recurrent, high-grade, IDH1-mutant gliomas in a Phase II study.

Revenue from the CAR T-cell therapy for later-line acute lymphoblastic leukemia more than doubled year-over-year.

BeOne has gained exclusive rights to develop and commercialize four Revolution candidates in certain Asian markets.

Researchers explored the effect of germline variants on toxicity in lymphoma patients from two clinical trials of Gilead's Yescarta.

PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.

Phase I/II SONIX trial will enroll 10 children with biallelic GJB2 variants to evaluate the gene therapy, called SKY-GJB2.

The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.

The deal centers on Actio's small molecule for KCNT1-related epilepsy. Meanwhile, Actio will spin out a separate company with its other assets.